FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: ***BIOSENTA INC.*** *(the "Issuer").*

Trading Symbol: ***ZRO***

Number of Outstanding Listed Securities: ***12,429,408***

Date: ***April 30, 2017***

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact

   By Articles of Amendment in the Province of Ontario dated June 22, 2016, the Company consolidated its issued and outstanding common shares ("Share Consolidation") on the basis of one (1) post-consolidation common shares for each fifteen (15) pre-consolidation common shares (the "Share Consolidation Ratio").

   If the Share Consolidation would otherwise result in a shareholder holding a fractional post-consolidation common share, the number of shares to be issued to such shareholder shall be rounded up to the next higher whole number, if the fraction is 0.5 or greater, and rounded down to the next lower whole number if the fraction is less than 0.5.

   The shares began trading on a consolidated basis on June 28, 2016.

   The resolution authorizing the amendment was approved at the annual and special meeting of shareholders held on June 14, 2016.

As disclosed in a press release dated March 1, 2016, the Company announced that on February 29, 2016 it received approval from the Ontario Superior Court of Justice to proceed with the implementation of the restructuring proposal to creditors (the "Proposal"). The Proposal was announced on November 19, 2015. The Proposal was made under the Canadian Bankruptcy and Insolvency Act (the Act). A copy has been filed on the Company's profile at www.sedar.com. The Proposal was approved by the board of the Company, which appointed Farber Financial Group as the trustee (the "Trustee"). By virtue of a court order, legal proceedings against the Company have been stayed at this time.

In May, 2016, the Company received Court approval to proceed with the Proposal to creditors as presented to creditors and report back to the Court when finished. The Company issued 99,117,020 common shares to settle the obligations with creditors that were involved with the Proposal. As disclosed in a press release dated June 13, 2016, the Company announced that the Proposal has been completed The completion of the Proposal means that the Company is debt free except for future possible cash payments to creditors.

As disclosed in a press release dated November 24, 2016, the Company announced that it has received from the United States Patent Office a patent recognizing the unique and proprietary technology employed to manufacture Tri-Filler powder.

2. Provide a general overview and discussion of the activities of management.

Core Business Strategy

The Company is developing two business units within the anti-microbial industry. Products within these business units are targeted to address the demand created by the mounting health and environmental concerns with mould. Mould can affect the immune system, nervous system, liver, kidneys, blood and cause brain damage.

Under the Company's Industrial Division, the Company plans to manufacture and distribute an anti-microbial filler called "Tri-filler". Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attract mould. Annual global revenue in the calcium carbonate filler industry is likely to be more than 100 billion dollars. Biosenta will produce anti-microbial filler that performs 'filling' and 'bulking' functions like calcium carbonate. Biosenta's filler product will not attract moisture and consequently mould infestation. Biosenta's filler with its anti-microbial high pH core in individual particles will enhance commercial product life and eradicate a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction. The Company has commissioned its production plant to produce the filler product located in Parry Sound, Ontario. It is currently producing test product for potential customers.

Under the Company's Consumer Division, the Company has developed a line of retail anti-microbial products that will effectively kill mould, bacteria and fungi on contact and prevent re-growth. The Company has obtained the necessary government approvals from Health Canada for selling its initial product line called Zeromold™ in Canada in September 2012. The first shipments of the product started in October 2012 on a limited basis within Canada. The Company has developed a second generation of this product generation currently called "True" and a third generation product line called "Purity".

Industrial Division: Tri-Filler

The Company will manufacture and distribute proprietary anti-microbial filler, and/or sub-license the technology relating thereto. Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attracting mould. The Company will produce anti-microbial filler that performs "filling" and "bulking" that will not attract moisture and consequently mould infestation. The Company's filler product with its anti-microbial high pH core in individual particles enhances commercial product life and eradicates a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction.

The Company completed the final construction phase of its production plant facility located in Parry Sound, Ontario in the three month period ended December 31, 2014. The Tri-Filler product is manufactured using advanced nano-encapsulation technology in a reactor. The Tri-Filler compound and the manufacturing process have been patented by Biosenta. The plant has a capacity of 2 tonnes per hour.

In December 2014 and January 2015, Tri-Filler product was successfully manufactured at the Parry Sound plant, and samples from the plant were examined at an independent laboratory to confirm that the particles were being manufactured to specification and that complete nano-encapsulation had occurred during production.

In March 2015, Tri-Filler was used by a large plastics manufacturer in its production plant, and the product manufactured using Tri-Filler was manufactured without any production issues. The next step is to test the product manufactured by the plant for anti-microbial, fire-retarding and strength properties at an independent laboratory. Biosenta expects these tests to be conducted within the next two months. Discussions with other potential customers to test Tri-Filler in industries, beyond plastics and resins, are also progressing and include the building, resin and plastics industries.

Tri-Filler has been successfully tested using ASTM G21 and G22 tests and is being evaluated by potential customers. Approvals from the U.S. EPA and Canadian PMRA have begun. In addition, discussions with the Canadian Standards Association will continue to define new product standards for Tri-Filler as it represents an innovative and unique product type.

As disclosed in a press release dated June 13, 2016, the Company announced that a CAS number has been assigned to Tri-Filler by the American Chemicals Association. The awarding of a CAS number for Tri-Filler supports the opinion of Biosenta that Tri-Filler is an unique chemical with properties that its constituents, pure calcium hydroxide and calcium carbonate do not possess unless combined using Biosenta's nano-technology.

As disclosed in a press release dated November 24, 2016, the Company announced that it has received from the United States Patent Office a patent recognizing the unique and proprietary technology employed to manufacture Tri-Filler powder.

As disclosed in a press release dated December 12, 2016, the Company announced that it has received its first purchase order for Tri-Filler for eight metric tonnes.

Consumer Division - Anti-Microbial Retail Product Line

Biosenta's household disinfectants and cleaners possess similar levels of efficacy as traditional disinfectants with significantly lower concentrations of active ingredients resulting in lower toxicity. These disinfectants and cleaners will kill 100% of potentially deadly mold, fungi, bacteria and viruses on contact and prevent re-growth. The disinfectants are very safe due to the very low toxicity. The Company has developed its first retail product line of anti-mould product called Zeromold™ and has made its first shipments in Canada starting in October 2012. The product rollout was limited for the fiscal years 2013 to 2015 due to limited cash flow and production control issues. As a result of the rollout of the product in Canada has been slow.

The Company's rollout of the product started in the last quarter of fiscal 2014. To date, Biosenta estimates that approximately 900 stores have received the product. Biosenta has also listed ZeroMold in two other retailers in Canada in the February and March 2015 time frame. The rollout to the stores was again limited as a result of limited working capital to finance the rollout to the different retailers.

As disclosed in a press release dated June 22, 2015, the Company announced that its disinfectant, called "True" has been approved by the Environmental Protection Agency (EPA) in the U.S.A. Further, the EPA has allowed True to not carry a warning, caution or danger label because it is very safe for human use.

True is a new disinfectant and cleaner which effectively kills a multitude of potentially deadly microbes (bacteria, viruses and fungi/ mould) with a formulation that has been shown to be very safe for use. The innovation which gives True its unique properties is that it is both a very powerful disinfectant and it contains very low levels of active ingredients which make it much less toxic and more safe.

Laboratory testing of True on a broad range of potentially deadly microbes has been conducted by a world renowned institution. These standardised tests have shown True will kill 100% of the following microbes within a 10 minute contact time:

Bacteria	**Virus**	**Fungi**
Acinetobacter Baumannii (ABC)	**Adenovirus**	**Black mould**
E. Coli	**Chlamydia**	**Trichophyton**
Listeria	**Ebola**	**mentagrophytes**
MRSA	**Enterovirus D68**	
Pseudomonas aeruginosa	**H1N1**	
Salmonella	**Hepatitis**	
Staphylococcus aureus	**Herpes**	
	HIV	
	Influenza	
	Polio	

Respiratory Syncytial Virus
Rotavirus
Swine Flu
Tuberculosis
Vaccina (pox virus)

Note that the Ebola and Enterovirus D68 claims are based on scientific rationale as provided by the U.S. Center for Disease Control. Please refer to Biosenta.com for details of the laboratory testing.

Approval to market and sell True in Canada is underway. The approval process in Canada was commenced in December, 2014, but the Company has not reach acceptable levels of approval yet.

In March 2015 the Company announced a third-generation disinfectant, to be called Purity, has been developed to possess faster anti-microbial action than True and with a low pH. Biosenta's product strategy is to provide products that are both safe and powerful, and Purity will fulfill this strategy and represent an innovative disinfectant relative to currently available disinfectants. Purity will be tested over the next two months at an independent laboratory to refine the formulation. The goal is to use Purity in hand sanitizer and wipes as well as a disinfectant.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   See Section 1 above regarding the "True" production line and see Section 2 in the Consumer Division regarding the "Purity" production line.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   N/A

8. Describe the acquisition of new customers or loss of customers.

   N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   As disclosed in a press release dated November 24, 2016, the Company announced that it has received from the United States Patent Office a patent recognizing the unique and proprietary technology employed to manufacture Tri-Filler powder.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

    N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

    N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    See bankruptcy proposal above

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    See bankruptcy proposal above.

14. Provide details of any securities issued and options or warrants granted.

    N/A

15. Provide details of any loans to or by Related Persons.

    As at March 31, 2017, there was an amount loaned from directors of the Company totalling $71,000. This payable is unsecured, non-interest bearing and due on demand. In addition, certain directors of the Company participated in the convertible debenture financing in the amount of $50,000.

16. Provide details of any changes in directors, officers or committee members.

    As disclosed in a press release dated November 1, 2016, the Company announced that Nicholas Iacono of New Canaan, Connecticut, U.S.A. and Amarvir Gill of Calgary, Alberta have joined its Board of Directors.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

    N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. *The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.*

2. *As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.*

3. *The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).*

4. *All of the information in this Form 7 Monthly Progress Report is true.*

Dated May 01, 2017

Dene Rogers
Name of Director or Senior Officer

Signature: "Dene Rogers"

Chairman
Official Capacity

Issuer Details *Name of Issuer* ***Biosenta Inc.***	*For Month End* ***JANUARY 2017***	*Date of Report* *YY/MM/D* ***2017/05/01***
Issuer Address ***18 Wynford Drive, Suite 704***		
City/Province/Postal Code ***Toronto, Ontario M3C 3S2***	*Issuer Fax No.* ***(416) 410-6703***	*Issuer Telephone No.* ***(416) 410-2019***
Contact Name ***Dene Rogers***	*Contact Position* ***Chairman***	*Contact Telephone No.* ***(416) 410-2019***
Contact Email Address ***dene@biosenta.com***	*Web Site Address* ***www.biosenta.com***	